Molecular Partners (MOLN) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic Focus and Technology Platforms

• Emphasis on patient value and pioneering therapies for high medical need using DARPin technology, now classified as mini proteins, with a 20-year track record and CHF 150 million in cash extending runway into 2027.

• Two main platforms: radiotherapy DARPins (delivering isotopes to tumors) and immune cell engagers (multi-specific T cell engagers), both positioned in high-interest fields.

• Proprietary DARPin engine supports rapid selection, development, and manufacturing of candidates, with global infrastructure for preclinical and clinical work.

• Partnerships with Orano Med (for isotope supply and development) and Novartis, with expanded collaboration to access up to 10 products using lead isotopes.

• Operations in Switzerland and the US, with a continued focus on leveraging DARPin differentiation to expand the portfolio and pursue new partnering opportunities.

Pipeline Progress and Clinical Updates

• Lead radiotherapy program MP0712 targets DLL3 in small cell lung cancer, showing strong tumor-to-kidney ratios, selective tumor targeting, potent efficacy, and promising preclinical safety.

• Phase 0 imaging for MP0712 to start in 2024, providing early value inflection and guiding phase 1 dosing; phase 2 planned for 2025, with initial clinical data expected by year-end.

• Mesothelin-targeting DARPin for ovarian cancer advancing, with binders designed to avoid shed antigen, targeting membrane-proximal epitopes, and updates expected at AACR.

• MP0533, a tetra-specific T cell engager for AML, showed improved response rates in higher dose cohorts, preliminary clinical responses, and improved exposure with amended dosing regimens.

• Switch-DARPin platform enables conditional immune cell activation and co-stimulation, enhancing tumor specificity and safety, with ongoing candidate selection, preclinical efficacy in solid tumor models, and partnership discussions.

Financials, Partnerships, and Outlook

• Well-capitalized with CHF ~149–150 million in cash, supporting operations and R&D through key value inflection points into 2027.

• Strategic partnership with Orano Med enables access to unique 212Pb supply, large-scale manufacturing, and rapid candidate development for up to 10 radiotherapy products.

• Orano Med and Sanofi provide manufacturing and commercialization support, with Sanofi involved in late-stage and supply chain buildout.

• Upcoming milestones include MP0712 phase 0 imaging data, mesothelin program updates, expanded Orano Med collaboration, further MP0533 clinical data, IND applications, and preclinical updates on the Switch platform in 2024–2025.

• Provided forward-looking statements regarding clinical milestones, regulatory filings, and business outlook for 2025 and beyond.